Internet-delivered cognitive behavioural therapy programme to reduce depressive symptoms in patients with multiple sclerosis: a multicentre, randomised, controlled, phase 3 trial

Gold, 2020, Comorbid depression in medical diseases, Nat Rev Dis Primers, 6, 69, 10.1038/s41572-020-0200-2 Marrie, 2017, Comorbidity in multiple sclerosis: implications for patient care, Nat Rev Neurol, 13, 375, 10.1038/nrneurol.2017.33 Boeschoten, 2017, Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis, J Neurol Sci, 372, 331, 10.1016/j.jns.2016.11.067 Siegert, 2005, Depression in multiple sclerosis: a review, J Neurol Neurosurg Psychiatry, 76, 469, 10.1136/jnnp.2004.054635 Whitehouse, 2019, Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders, Neurology, 92, e406, 10.1212/WNL.0000000000006854 Washington, 2022, Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review, J Neurol, 269, 1861, 10.1007/s00415-021-10850-w Prisnie, 2018, Effects of depression and anxiety on quality of life in five common neurological disorders, Gen Hosp Psychiatry, 52, 58, 10.1016/j.genhosppsych.2018.03.009 Disanto, 2018, Prodromal symptoms of multiple sclerosis in primary care, Ann Neurol, 83, 1162, 10.1002/ana.25247 Binzer, 2019, Disability worsening among persons with multiple sclerosis and depression: a Swedish cohort study, Neurology, 93, e2216, 10.1212/WNL.0000000000008617 McKay, 2018, Psychiatric comorbidity is associated with disability progression in multiple sclerosis, Neurology, 90, e1316, 10.1212/WNL.0000000000005302 Marrie, 2018, Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases, Gen Hosp Psychiatry, 53, 65, 10.1016/j.genhosppsych.2018.06.001 Palladino, 2021, Interface of multiple sclerosis, depression, vascular disease, and mortality: a population-based matched cohort study, Neurology, 97, e1322, 10.1212/WNL.0000000000012610 Minden, 2014, Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology, Neurology, 82, 174, 10.1212/WNL.0000000000000013 Koch, 2011, Pharmacologic treatment of depression in multiple sclerosis, Cochrane Database Syst Rev, 2 Hind, 2014, Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis, BMC Psychiatry, 14, 5, 10.1186/1471-244X-14-5 Ghielen, 2019, The effects of cognitive behavioral and mindfulness-based therapies on psychological distress in patients with multiple sclerosis, Parkinson's disease and Huntington's disease: two meta-analyses, J Psychosom Res, 122, 43, 10.1016/j.jpsychores.2019.05.001 Mohr, 2005, Telephone-administered psychotherapy for depression, Arch Gen Psychiatry, 62, 1007, 10.1001/archpsyc.62.9.1007 Karyotaki, 2021, Internet-based cognitive behavioral therapy for depression: a systematic review and individual patient data network meta-analysis, JAMA Psychiatry, 78, 361, 10.1001/jamapsychiatry.2020.4364 White, 2022, Online psychological interventions to reduce symptoms of depression, anxiety, and general distress in those with chronic health conditions: a systematic review and meta-analysis of randomized controlled trials, Psychol Med, 52, 548, 10.1017/S0033291720002251 Fischer, 2015, An online programme to reduce depression in patients with multiple sclerosis: a randomised controlled trial, Lancet Psychiatry, 2, 217, 10.1016/S2215-0366(14)00049-2 Boeschoten, 2017, Internet-based treatment for depression in multiple sclerosis: a randomized controlled trial, Mult Scler, 23, 1112, 10.1177/1352458516671820 Sesel, 2022, A randomized controlled trial of a web-based mindfulness programme for people with MS with and without a history of recurrent depression, Mult Scler, 28, 1392, 10.1177/13524585211068002 Polman, 2011, Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Ann Neurol, 69, 292, 10.1002/ana.22366 Hohol, 1995, Disease steps in multiple sclerosis: a simple approach to evaluate disease progression, Neurology, 45, 251, 10.1212/WNL.45.2.251 Kurtzke, 1983, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, 33, 1444, 10.1212/WNL.33.11.1444 Langdon, 2012, Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), Mult Scler, 18, 891, 10.1177/1352458511431076 Twomey, 2017, Effectiveness of an individually-tailored computerised CBT programme (Deprexis) for depression: a meta-analysis, Psychiatry Res, 256, 371, 10.1016/j.psychres.2017.06.081 Meyer, 2009, Effectiveness of a novel integrative online treatment for depression (Deprexis): randomized controlled trial, J Med Internet Res, 11, e15, 10.2196/jmir.1151 Berger, 2011, Internet-based treatment of depression: a randomized controlled trial comparing guided with unguided self-help, Cogn Behav Ther, 40, 251, 10.1080/16506073.2011.616531 Watson, 2014, Validation of mood measures for people with multiple sclerosis, Int J MS Care, 16, 105, 10.7224/1537-2073.2013-013 Holländare, 2010, A comparison of psychometric properties between internet and paper versions of two depression instruments (BDI-II and MADRS-S) administered to clinic patients, J Med Internet Res, 12, e49, 10.2196/jmir.1392 Skevington, 2004, The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group, Qual Life Res, 13, 299, 10.1023/B:QURE.0000018486.91360.00 Hobart, 2001, The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure, Brain, 124, 962, 10.1093/brain/124.5.962 Penner, 2009, The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue, Mult Scler, 15, 1509, 10.1177/1352458509348519 Cella, 2010, Measuring fatigue in clinical and community settings, J Psychosom Res, 69, 17, 10.1016/j.jpsychores.2009.10.007 Montgomery, 1979, A new depression scale designed to be sensitive to change, Br J Psychiatry, 134, 382, 10.1192/bjp.134.4.382 Osman, 2001, The Suicidal Behaviors Questionnaire-Revised (SBQ-R): validation with clinical and nonclinical samples, Assessment, 8, 443, 10.1177/107319110100800409 Button, 2015, Minimal clinically important difference on the Beck Depression Inventory—II according to the patient's perspective, Psychol Med, 45, 3269, 10.1017/S0033291715001270 Mallinckrodt, 2003, Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations, J Biopharm Stat, 13, 179, 10.1081/BIP-120019265 Cohen, 1988 2009 Gold, 2019, Differential impact of affective and cognitive symptoms on remission of major depression, Lancet Psychiatry, 6, 980, 10.1016/S2215-0366(19)30384-0 Garjani, 2021, Recovery from COVID-19 in multiple sclerosis: a prospective and longitudinal cohort study of the United Kingdom Multiple Sclerosis Register, Neurol Neuroimmunol Neuroinflamm, 9 Gold, 2017, Control conditions for randomised trials of behavioural interventions in psychiatry: a decision framework, Lancet Psychiatry, 4, 725, 10.1016/S2215-0366(17)30153-0